Commentary
Video
Achieving Chronic Spontaneous and Inducible Urticaria Control With Barzolvolimab, with Martin Metz, MD
Author(s):
Metz shared highlights from 2 presentations he gave on barzolvolimab’s efficacy at the AAAAI/WAO Joint Congress.
Barzolvolimab yielded high rates of disease control in patients with chronic spontaneous urticaria (CSU) and inducible urticaria.1
These findings, from 2 phase 2 trials, were presented at the 2025 American Academy of Allergy, Asthma, and Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress, February 28-March 3, in San Diego, California, by Martin Metz, MD, professor, Department of Dermatology and Allergology and head of translational research and deputy head of clinical trials at Charité – Universitätsmedizin in Berlin and head of preclinical research of mast cell–mediated diseases at the Fraunhofer Institute for Translational Medicine and Pharmacology– Allergology and Immunology in Berlin.
HCPLive® spoke with Metz to learn more about barzolvolimab’s efficacy and safety profile, and how it could benefit the treatment landscapes for both CSU and inducible urticaria, especially since there are no therapies currently approved for the latter indication. He explained the therapy’s mechanism and how it targets mast cells to control disease, and noted that it may benefit other diseases such as prurigo nodularis, which barzolvolimab is also currently being evaluated in.
“So overall, very high rate of patients who showed control of the disease, both in inducible and in spontaneous. And this is something very important. We need new treatment options in case of CSU and a real first treatment option for inducible, because at the moment, we don't have any approved drug for inducible urticaria,” Metz said.
Metz's relevant disclosures include AbbVie, Advanz, ALK-Abello, Allegria, Almirall, Amgen, Argenx, AstraZeneca, Astria, Attovia, Berlin-Chemie, Celldex, Celltrion, DeepApple, Escient, Ga2len, Galderma, gsk, Incyte, Jasper, Lilly, Novartis, Pfizer, Pharvaris, Regeneron, Sanofi, Santa Ana Bio, Septerna, Teva, ThirdHarmonicBio, and Vaifor.
REFERENCES
Metz M, Maurer M, Kobielusz-Gembala I, et al. Barzolvolimab Improves Urticaria Control and Quality of Life in Patients with Chronic Spontaneous Urticaria: 52-Week Data. Presented at: 2025 AAAAI/WAO Joint Congress, February 28-March 3. Abstract L11
Metz M, Maurer M, Arnau AMG, et al. Treatment with Barzolvolimab Improves Urticaria Control and Quality of Life in Patients with Chronic Inducible Urticaria: Phase 2 12 Week Results. Abstract 183
